Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations.

Halseth AE, Ensor NJ, White TA, Ross SA, Gulve EA

Biochemical and biophysical research communications1 Jun 2002Cited by 53 (Europe PMC)

PMID12061777DOI10.1016/s0006-291x(02)00557-0PepBankPUB-12061777

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In db/db and ob/ob mice, acute AICAR transiently lowered glucose, which returned to basal levels approximately three hours later.
In plain wordsIn mice, AICAR temporarily lowered blood sugar from starting levels.
Peptide
AICAR (acadesine)
Outcome
DecreaseAcute blood glucose
Study
mousen: not reported in source
db/db and ob/ob mice
Comparator
Basal levels
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · single injectionAs given in this study (mouse).
Measurements
Return to basal glucose
≈ 3 h
after acute AICAR
Source sentences
Summary
Blood glucose was lowered transiently in both db/db and ob/ob mice by acute AICAR treatment, returning to basal levels approximately 3 h after AICAR administration.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effects of AMPK activation in animal models of type II diabetes, db/db and ob/ob mice were administered 5-aminoimidazole-4-carboxamide 1-beta-ribofuranoside (AICAR) subcutaneously either acutely (single injection) or twice per day for 8 days (chronic treatment).
Report a problemFND-1206177701
02AnimalAnimal study (in vivo)Efficacy outcome
In db/db and ob/ob mice, chronic AICAR decreased morning glucose approximately 30-35% versus vehicle on Day 8.
In plain wordsIn mice, repeated AICAR reduced morning blood sugar compared with vehicle.
Peptide
AICAR (acadesine)
Outcome
DecreaseChronic blood glucose
Study
mousen: not reported in source
db/db and ob/ob mice
Comparator
Vehicle
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 8 daysAs given in this study (mouse).
Measurements
Blood glucose decrease
30 to 35%
Day 8, both models
Source sentences
Summary
In response to chronic treatment, blood glucose (measured 18 h post-AICAR administration) was significantly decreased in both mouse models when compared to vehicle control groups, with morning blood glucose values on Day 8 being decreased approximately 30-35% in both mouse models.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effects of AMPK activation in animal models of type II diabetes, db/db and ob/ob mice were administered 5-aminoimidazole-4-carboxamide 1-beta-ribofuranoside (AICAR) subcutaneously either acutely (single injection) or twice per day for 8 days (chronic treatment).
Report a problemFND-1206177702
03AnimalAnimal study (in vivo)Mechanism
In mice, chronic AICAR increased total muscle GLUT4 in ob/ob but not db/db mice.
In plain wordsIn mice, repeated AICAR increased muscle GLUT4 in ob/ob mice but not db/db mice.
Peptide
AICAR (acadesine)
Outcome
MixedTotal muscle GLUT4
Study
mousen: not reported in source
db/db and ob/ob mice
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 8 daysAs given in this study (mouse).
Source sentences
Summary
Chronic AICAR administration also resulted in an elevation of total Glut4 concentration in skeletal muscle from ob/ob mice, but not db/db mice.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effects of AMPK activation in animal models of type II diabetes, db/db and ob/ob mice were administered 5-aminoimidazole-4-carboxamide 1-beta-ribofuranoside (AICAR) subcutaneously either acutely (single injection) or twice per day for 8 days (chronic treatment).
Report a problemFND-1206177703
04AnimalAnimal study (in vivo)Safety outcome
In db/db and ob/ob mice, AICAR increased serum triglycerides approximately 2.5-3-fold versus vehicle.
In plain wordsIn mice, AICAR increased blood triglycerides compared with vehicle.
Peptide
AICAR (acadesine)
Outcome
IncreaseSerum triglycerides
Study
mousen: not reported in source
db/db and ob/ob mice
Comparator
Vehicle
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (mouse).
Measurements
Triglyceride increase
2.5 to 3 fold
both mouse models
Source sentences
Summary
In contrast to the beneficial effects on glucose metabolism, AICAR treatment of db/db and ob/ob mice led to approximately a 2.5-3-fold increase in serum triglyceride levels compared to vehicle-treated controls.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effects of AMPK activation in animal models of type II diabetes, db/db and ob/ob mice were administered 5-aminoimidazole-4-carboxamide 1-beta-ribofuranoside (AICAR) subcutaneously either acutely (single injection) or twice per day for 8 days (chronic treatment).
Report a problemFND-1206177704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations.

Summary

Results from this study4

Version history

Subjects

Publication types

MeSH terms